SELLAS Life Sciences Group, Inc.
(NASDAQ : GALE)

( )
GALE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.44%185.971.2%$605.33m
CELGCelgene Corporation
0.00%78.801.2%$532.62m
GILDGilead Sciences, Inc.
-0.56%70.670.9%$515.72m
BIIBBiogen Inc.
0.00%296.041.2%$437.32m
NKTRNektar Therapeutics
0.06%52.885.6%$413.22m
SRPTSarepta Therapeutics, Inc.
1.44%142.3516.6%$361.50m
VRTXVertex Pharmaceuticals Incorporated
0.00%159.191.9%$269.27m
REGNRegeneron Pharmaceuticals, Inc.
0.00%331.972.6%$248.01m
ILMNIllumina, Inc.
0.00%282.653.5%$212.82m
BLUEBluebird Bio, Inc.
-0.53%168.0015.7%$193.26m
EXASExact Sciences Corporation
0.00%66.3325.4%$180.98m
AAgilent Technologies, Inc.
0.00%62.791.5%$178.44m
ALXNAlexion Pharmaceuticals, Inc.
0.00%127.572.0%$159.93m
BMRNBioMarin Pharmaceutical Inc.
0.00%99.034.4%$141.99m
INCYIncyte Corporation
0.00%74.032.5%$133.28m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.